Christelle Darstein

1.7k total citations
36 papers, 1.3k citations indexed

About

Christelle Darstein is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Genetics. According to data from OpenAlex, Christelle Darstein has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Christelle Darstein's work include Pituitary Gland Disorders and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Neuroendocrine Tumor Research Advances (7 papers). Christelle Darstein is often cited by papers focused on Pituitary Gland Disorders and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Neuroendocrine Tumor Research Advances (7 papers). Christelle Darstein collaborates with scholars based in United States, Switzerland and Germany. Christelle Darstein's co-authors include Christopher D. Payne, Kenneth J. Winters, John T. Brandt, Joseph A. Jakubowski, Tomas Jernberg, Hideo Naganuma, Agneta Siegbahn, Lars Wallentin, C. Steven Ernest and Nazar Farid and has published in prestigious journals such as Journal of Clinical Oncology, Blood and CHEST Journal.

In The Last Decade

Christelle Darstein

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christelle Darstein United States	14	717	389	259	187	186	36	1.3k
Jean‐François Abgrall France	21	785 1.1×	345 0.9×	296 1.1×	100 0.5×	413 2.2×	34	2.1k
Brian A. Moser United States	14	419 0.6×	242 0.6×	131 0.5×	114 0.6×	104 0.6×	24	935
Keiji Takazoe Japan	20	615 0.9×	438 1.1×	316 1.2×	93 0.5×	136 0.7×	31	1.5k
Giuseppe G. Nenci Italy	25	621 0.9×	417 1.1×	120 0.5×	122 0.7×	433 2.3×	100	1.9k
J.A. Jakubowski United States	17	410 0.6×	230 0.6×	129 0.5×	259 1.4×	183 1.0×	32	1.3k
J.J.J. van Giezen Sweden	20	1.3k 1.8×	441 1.1×	139 0.5×	45 0.2×	542 2.9×	41	1.9k
Isabell Bernlochner Germany	23	993 1.4×	505 1.3×	109 0.4×	82 0.4×	376 2.0×	62	1.4k
Angela M. Carter United Kingdom	20	445 0.6×	161 0.4×	222 0.9×	42 0.2×	152 0.8×	30	1.5k
Juan J. Badimon United States	24	1.1k 1.5×	998 2.6×	134 0.5×	108 0.6×	254 1.4×	66	2.2k
Peter Santer Austria	18	477 0.7×	789 2.0×	377 1.5×	206 1.1×	34 0.2×	26	2.5k

Countries citing papers authored by Christelle Darstein

Since Specialization

Citations

This map shows the geographic impact of Christelle Darstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christelle Darstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christelle Darstein more than expected).

Fields of papers citing papers by Christelle Darstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christelle Darstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christelle Darstein. The network helps show where Christelle Darstein may publish in the future.

Co-authorship network of co-authors of Christelle Darstein

This figure shows the co-authorship network connecting the top 25 collaborators of Christelle Darstein. A scholar is included among the top collaborators of Christelle Darstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christelle Darstein. Christelle Darstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Darstein, Christelle, Dok Hyun Yoon, Yiqun Yang, et al.. (2025). Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology. 95(1). 39–39. 1 indexed citations

Sy, Sherwin K. B., Yiqun Yang, Christelle Darstein, et al.. (2025). Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Cancer Chemotherapy and Pharmacology. 95(1). 83–83.

Sy, Sherwin K. B., Christelle Darstein, Yiqun Yang, et al.. (2024). Population modelling of nilotinib exposure vs . longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model. British Journal of Clinical Pharmacology. 91(5). 1419–1430. 1 indexed citations

Ji, Yan, Hilmar Schiller, Michelle Quinlan, et al.. (2024). Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical Pharmacokinetics. 63(2). 155–170. 2 indexed citations

Ji, Yan, Christelle Darstein, Michelle Quinlan, et al.. (2023). Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer. The Journal of Clinical Pharmacology. 63(12). 1359–1370. 7 indexed citations

Pavel, Marianne, Françoise Borson‐Chazot, Anne Cailleux, et al.. (2018). Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemotherapy and Pharmacology. 83(2). 375–385. 25 indexed citations

Ting, Lillian, Nicholas Sauter, Christelle Darstein, et al.. (2017). Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. Clinical Drug Investigation. 37(5). 465–472. 30 indexed citations

Chen, Xia, Guoxiang Shen, Ji Jiang, et al.. (2014). Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study. Clinical Therapeutics. 36(8). 1196–1210. 11 indexed citations

Breitschaft, Astrid, Ke Hu, Karina Hermosillo Reséndiz, Christelle Darstein, & Georg Golor. (2013). Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabetes Research and Clinical Practice. 103(3). 458–465. 90 indexed citations

10.

Beglinger, Christoph, Ke Hu, Ying Wang, et al.. (2012). Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine. 42(2). 366–374. 15 indexed citations

11.

Glimelius, Bengt, Michael Lahn, Ann Cleverly, et al.. (2009). A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Annals of Oncology. 21(5). 1020–1026. 22 indexed citations

12.

Vergote, Ignace, Frédéric Amant, Luna Musib, et al.. (2009). Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer Results From a Safety Lead-in Study. International Journal of Gynecological Cancer. 19(9). 1505–1510. 7 indexed citations

13.

Camidge, D. Ross, S. Gail Eckhardt, Lia Gore, et al.. (2008). A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anti-Cancer Drugs. 19(1). 77–84. 23 indexed citations

14.

Specenier, Pol, Tudor–Eliade Ciuleanu, Jane E. Latz, et al.. (2008). Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemotherapy and Pharmacology. 64(2). 233–241. 14 indexed citations

15.

Welch, Pamela A., Vikram Sinha, Ann Cleverly, et al.. (2007). Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C‐β Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology. 47(9). 1138–1151. 16 indexed citations

16.

Farid, Nazar, Christopher D. Payne, D. S. Small, et al.. (2007). Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently. Clinical Pharmacology & Therapeutics. 81(5). 735–741. 248 indexed citations

17.

Guillaume, Michel, et al.. (2007). Hemodynamic Interaction Between a Daily Dosed Phosphodiesterase 5 Inhibitor, Tadalafil, and the α‐Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle‐Aged Healthy Male Subjects. The Journal of Clinical Pharmacology. 47(10). 1303–1310. 14 indexed citations

18.

Hanauske, Axel-Rainer, Luna Musib, K. Weigang-Köhler, et al.. (2007). Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study. Journal of Clinical Oncology. 25(18_suppl). 14021–14021. 1 indexed citations

19.

Hanauske, A.-R., Bart C. Kuenen, D. Thornton, et al.. (2006). Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 24(18_suppl). 2047–2047. 9 indexed citations

20.

Jernberg, Tomas, Christopher D. Payne, Kenneth J. Winters, et al.. (2006). Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European Heart Journal. 27(10). 1166–1173. 424 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact